Source - LSE Regulatory
RNS Number : 3951H
Cambridge Cognition Holdings PLC
06 April 2022
 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Senior Management Appointments

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce two senior management appointments.

 

Stephen Symonds has joined the Company as its new Chief Financial Officer and is expected to join the board in due course.  Stephen is an experienced finance professional and was until recently the Chief Financial Officer of Envigo, a private equity backed provider of pre-clinical services for the pharmaceutical industry, where he spent eight years.  Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.  Earlier in his career, he built a broad experience in a variety of small to medium-size accounting companies and as the finance lead in a family-owned business.

 

The board would like to thank Nick Walters for providing the Company with interim financial leadership while the Chief Financial Officer recruitment process was conducted.

 

Francesca Cormack has been appointed as the Company's Chief Scientist, having spent seven years at Cambridge Cognition, most recently as Director of Research and Innovation.  Francesca will lead the Company's research and development activities and act as the Company's scientific leader, with a view to enhancing its competitive position and supporting its long-term business success.  She is also an honorary senior research fellow at Cambridge University's department of psychiatry.

 

Jenny Barnett, currently Chief Scientific Officer, will be stepping down from the Company at the end of April 2022 to focus her efforts on Monument Therapeutics.  Monument Therapeutics was spun out from Cambridge Cognition in July 2021 and continues to work closely with the Company using its cognitive assessments as core elements of their developments.

 

For further information, contact:

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Steven Powell, Chairman

Tel: 012 2381 0700

press@camcog.com

Panmure Gordon (NOMAD and Joint Broker)

Freddy Crossley / Emma Earl / Mark Rogers

Rupert Dearden

Tel: 020 7886 2500

(Corporate Advisory)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEANLSELDAEFA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.